Abstract: A micro light-emitting diode including an epitaxy structure, a first pad, a first ohmic contact layer and a current conducting layer is provided. The epitaxy structure includes a first type semiconductor layer, a second type semiconductor layer and an active layer. The first pad is electrically connected to the first type semiconductor layer. The first ohmic contact layer is electrically connected between the first type semiconductor layer and the first pad. The current conducting layer is electrically connected between the first ohmic contact layer and the first pad. At least a portion of the orthogonal projection of the first ohmic contact layer on the plane upon which the first type semiconductor layer is located is away from the orthogonal projection of the first pad on the plane. A display panel is also provided.

Abstract: A micro light emitting diode including an epitaxy layer, a first pad, a second pad, a first ohmic contact metal, a second ohmic contact metal and at least one etch protection conductive layer is provided. The first pad and the second pad are electrically connected to a first type semiconductor layer and a second type semiconductor layer of the epitaxy layer, respectively. The first ohmic contact metal is disposed between the first type semiconductor layer and the first pad. The second ohmic contact metal is disposed between the second type semiconductor layer and the second pad. The at least one etch protection conductive layer is disposed between the first ohmic contact metal and the first pad and/or between the second ohmic contact metal and the second pad. A display panel is also provided.

Abstract: A micro light-emitting diode is provided. The micro light-emitting diode includes a first-type semiconductor layer having a first doping type; a light-emitting layer over the first-type semiconductor layer; a first-type electrode over the first-type semiconductor layer; a second-type semiconductor layer having a second doping type over the light-emitting layer, wherein the second doping type is different from the first doping type; a second-type electrode over the second-type semiconductor layer; and a barrier layer under the first-type semiconductor layer and away from the first-type electrode and the second-type electrode, wherein the barrier layer includes a doped region having the second doping type.

Abstract: Disclosed is a total flavonoids extract of Gynura formosana Kitam., containing 80%-85% of rutin by weight percent content. The results of pharmacological experiments show that the extract can lower the activity of xanthine oxidase in the liver of a hyperuricemia model mouse and reduce the synthesis of uric acid to a certain degree and has a certain uric acid-lowering effect, and can be used as a potential drug for treating hyperuricemia or gout. The method for preparing the total flavonoids extract of Gynura formosana Kitam. comprises: after an extraction step, selecting a complex enzyme composed of enzymes with a specific composition and a specific ratio for enzymolosis, and further carrying out the step of extracting and concentrating with macroporous resin and isolating and purifying with macroporous resin, so that the HPLC purity of rutin in the resulting total flavonoids extract of Gynura formosana Kitam. reaches 80%-85%.

Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.

Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.

Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising, in weight percent, 80-85% of rutin. A method for preparing the total flavonoid extract from Gynura formosana Kitam. comprises solvent extraction, complex enzymatic hydrolysis, and separation and purification by a macroporous resin. The total flavonoid extract from Gynura formosana Kitam. is used to prepare a drug or health product related to alcoholic fatty liver disease.

Abstract: The present disclosure relates to a method and a device for categorizing multimedia resources. The method includes: counting the numbers of icons for respective types of icons input by a user for a multimedia resource; and determining a category to which the multimedia resource belongs according to the numbers of the respective types of icons input for the multimedia resource. The method and device for categorizing multimedia resources according to the present disclosure can take respective types of icons input by the user for the multimedia resources into consideration when categorizing the multimedia resources, thereby improving the accuracy of the categorization of the multimedia resources.

Abstract: The present disclosure relates to a method and a device for categorizing multimedia resources. The method includes: counting the numbers of icons for respective types of icons input by a user for a multimedia resource; and determining a category to which the multimedia resource belongs according to the numbers of the respective types of icons input for the multimedia resource. The method and device for categorizing multimedia resources according to the present disclosure can take respective types of icons input by the user for the multimedia resources into consideration when categorizing the multimedia resources, thereby improving the accuracy of the categorization of the multimedia resources.

Abstract: A micro light emitting device including a component layer, a first electrode and a second electrode is provided. The component layer includes a main body and a protruding structure disposed on the main body. The first electrode is electrically connected to the component layer. The second electrode is electrically connected to the component layer. The first electrode, the second electrode and the protruding structure are disposed on the same side of the main body. The protruding structure is located between the first electrode and the second electrode. A connection between the first electrode and the second electrode traverses the protruding structure. The main body has a surface. The protruding structure has a first height with respect to the surface. Any one of the first electrode and the second electrode has a second height with respect to the surface. The relation 0.8?H1/H2?1.2 is satisfied, wherein H1 is the first height and H2 is the second height.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Disclosed is a total flavonoids extract of Gynura formosana Kitam., containing 80%-85% of rutin by weight percent content. The results of pharmacological experiments show that the extract can lower the activity of xanthine oxidase in the liver of a hyperuricemia model mouse and reduce the synthesis of uric acid to a certain degree and has a certain uric acid-lowering effect, and can be used as a potential drug for treating hyperuricemia or gout. The method for preparing the total flavonoids extract of Gynura formosana Kitam. comprises: after an extraction step, selecting a complex enzyme composed of enzymes with a specific composition and a specific ratio for enzymolosis, and further carrying out the step of extracting and concentrating with macroporous resin and isolating and purifying with macroporous resin, so that the HPLC purity of rutin in the resulting total flavonoids extract of Gynura formosana Kitam. reaches 80%-85%.

Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising, in weight percent, 80-85% of rutin. A method for preparing the total flavonoid extract from Gynura formosana Kitam. comprises solvent extraction, complex enzymatic hydrolysis, and separation and purification by a macroporous resin. The total flavonoid extract from Gynura formosana Kitam. is used to prepare a drug or health product related to alcoholic fatty liver disease.

Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.